Articles tagged with Breast Cancer
A new study suggests that the nuclear receptor TLX can inhibit the growth and progression of triple-negative breast cancer. TLX+ cells showed lower tumor growth, migration, and invasion rates compared to those without TLX expression.
A new treatment approach for triple-negative breast cancer is being developed using nitric oxide scavengers. The study found that converting nitric oxide into nitrogen centred free radicals inhibits the migration of cancer cells in the tumor environment, suggesting a potential use of modified hyaluronic acid as a key material.
A Swedish study of 1,275 women with breast cancer found no increased risk of disease recurrence or death after fertility preservation procedures. The research provides new hope for women who want to preserve their fertility after cancer treatment.
A study from Lund University found that Caveolin-1 protein levels in surrounding tumour tissue affect breast cancer prognosis. The study suggests that this protein could be used as a marker for precise prognosis and treatment choice.
A pilot study from UCLA researchers found that neurofeedback training significantly normalized brain wave frequencies and improved cognitive function in cancer patients with chemo brain. The study's results support further research into the effectiveness of neurofeedback as a treatment approach.
Recent evidence suggests hormone therapy at menopause does not significantly increase the risk of invasive breast cancer. However, estrogen combined with progesterone increases breast cancer risk for women with an intact uterus. Menopause experts offer reassurance to women and their healthcare providers about the safety of hormone ther...
A recent study found associations between socioeconomic stressors and specific N-glycosylation patterns in Black and White women, suggesting that molecular markers may be linked to socioeconomic status. The research also identified differences in glycosylation patterns in normal breast tissue based on body mass index (BMI) and ancestry.
Scientists at Baylor College of Medicine and the Broad Institute have identified biological markers associated with chemotherapy resistance in triple negative breast cancer. The study found that deletion on chromosome 19, specifically the LIG1 gene, is linked to resistance to treatment and poor clinical outcomes.
SUTD researchers leverage nanosecond electroporation to deliver cancer-related molecules into living cells with excellent viability. The platform enables pores to remain open for up to 720 minutes, paving the way for efficient drug delivery and other applications.
Researchers developed a method combining musical tests with EEG measurement to detect cognitive decline in old age. The study tested 50 elderly people who scored low on the mini-mental test, showing promising results in detecting mental deterioration.
Research suggests that cancer-related fatigue (CRF) contributes to balance problems in breast cancer survivors, even after chemotherapy. CRF predicts greater postural sway and changes in 'sit-to-stand' function, highlighting the need for rehabilitation professionals to consider CRF in exercise prescriptions.
A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.
Researchers found lower stages of breast cancer in women aged 40-49 compared to those aged 50-59, with a significant decrease in stage 4 cases. This suggests that early detection through regular mammograms can lead to better health outcomes and survival rates.
Scientists have found a potential link between follicle stimulating hormone (FSH) levels and postmenopausal obesity, which increases the risk of breast cancer. The study will analyze data from the Women's Health Initiative to understand the relationship between FSH and abdominal obesity.
Researchers discovered that high levels of collagen type XII can trigger breast cancer cells to spread from the tumour to other parts of the body. The study suggests that measuring collagen XII levels in a patient's tumour biopsy could be used as an additional screening tool to identify aggressive breast cancers.
Researchers have identified key molecular differences between cancer cells that cling to initial tumors and those that spread to distant sites. The study found unique properties in cells that gain migratory ability and survival advantages, leading to the development of new treatment targets.
Researchers at Dartmouth Cancer Center developed a new approach for detecting and quantifying tumor heterogeneity in breast cancer. High levels of heterogeneity are linked to poor patient outcomes, while specific proteins regulate its extent. The study aims to utilize this approach in therapeutic decision-making.
Researchers at Queen's University Belfast have secured a £228,900 grant to develop an mRNA vaccine targeting protein p53 in triple negative breast cancer. The project aims to improve treatment options for patients with this aggressive form of the disease.
Researchers analyzed genomic data from 44 women with germline PTEN mutations who developed breast cancer and compared it to sporadic breast cancers. They found that PTEN and PIK3CA were the most frequently somatically mutated genes in PHTS-associated breast cancers, indicating that somatic mutations in PTEN drive these cancers.
A study found that cold temperatures activate brown adipose tissue that competes with tumors for glucose, inhibiting tumor growth and prolonging survival. Researchers suggest that cold therapy could be a promising approach to cancer therapy.
Researchers at NUS Medicine have successfully used a plant-derived nutrient supplement to shrink breast cancer tumors in preclinical models. The treatment, which uses nanotechnology to convert the natural component into chemotherapy only at the tumor site, shows promise for reducing side effects and increasing patient lifespan.
A new study by CU Anschutz researchers found that over 70% of breast cancer patients experience changes in their sexual health during and after treatment. Patients desire early education and counseling from medical teams to address these issues, which are often overlooked.
A researcher studied the 'black box' phenomenon in breast cancer survivorship care, revealing communication gaps between women and their providers. She found that black boxing can hide service access complexities, emphasizing the need for improved information pathways to address post-treatment needs.
A phase I/II clinical trial found that treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab plus chemotherapy. The study's results suggest that improving healthcare access and delivery could mitigate some of the existing disparities in healthcare.
A new study found an inverse association between breast cancer risk and n-3 PUFA consumption, especially in premenopausal women who are obese. Higher intake of marine n-3 PUFAs and total n-3 PUFAs was associated with a lower risk of breast cancer.
A new study found that over half of adult cancer survivors experience significant hearing problems after chemotherapy treatment. The researchers also discovered that platinum and taxane drugs, commonly used to treat the majority of cancers, are linked to high rates of hearing loss and tinnitus.
A study found that informing children about their mother's genetic cancer risk has no impact on their lifestyle or quality of life. Children of mothers with BRCA gene mutations were more concerned and knowledgeable about cancer, but this did not influence their behavior.
A large cohort study found that hormone replacement therapy for breast cancer survivors is not associated with an increased risk of recurrence. The study included over 8,400 Danish postmenopausal women and found no link between vaginal estrogen or menopausal hormone therapy and breast cancer reoccurrence.
The NHS Breast Screening Programme is associated with modest overdiagnosis of breast cancer, estimated at 3.7% of screen detected cancers. However, the benefits of screening in preventing deaths from breast cancer outweigh this risk, according to a recent study.
A systematic review and meta-analysis of 39 publications found a global association between COVID-19 measures and reduced breast, colorectal, and cervical cancer screenings. This could lead to an increase in avoidable cancer deaths.
A $3.1 million grant will enable researchers to collaborate on a prospective study investigating early signs of heart vessel damage in young, pre-menopausal breast cancer survivors. The CROWN study aims to identify biomarkers that correlate with cardiovascular risk and develop strategies to lower the risk of irreversible heart disease.
Abemaciclib, a CDK4 & 6 inhibitor, showed profound inhibition of cell proliferation and triggered senescence and apoptosis in breast cancer cells. Continuous dosing provided sustained inhibition with irreversible effects through apoptosis, supporting the differentiated safety and efficacy profile.
A recent study of over 5,000 women found that having a baby after breast cancer diagnosis does not negatively impact survival rates. Women who had hormone-receptor positive breast cancer and became mothers showed similar or increased survival compared to those without children.
CU Cancer Center member Ryan Layer developed a method to scan thousands of DNA samples using big data, identifying common benign mutations. This approach helps reduce false negatives in detecting complex DNA mutations associated with cancers.
Research from RCSI University of Medicine and Health Sciences found a link between high von Willebrand Factor levels and poorer breast cancer outcomes. High levels in the bloodstream can increase the risk of life-threatening blood clots and cancer spread in patients.
Researchers at LSU Health Sciences Center have discovered a novel combination therapy that effectively treats chemo-resistant triple-negative breast cancer. The treatment combines two existing FDA-approved drugs, ceritinib and enzalutamide, to target the growth of cancer cells, showing promise for improving treatment outcomes.
The report shows that the number of cancer survivors in the US has grown to 18 million as of January 2022. More than two-thirds (67%) of these survivors are aged 65 years or older. Racial disparities have been found in treatment and survival rates for common cancers.
Researchers at Baylor College of Medicine have identified a potential more effective treatment for HER2 mutant metastatic breast cancer, poziotinib. The drug reduced tumor growth and multi-organ metastasis in laboratory tests and animal models.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
A novel liquid biopsy test can accurately detect cancer DNA in the blood of patients with metastatic breast cancer within five hours, potentially helping oncologists determine if treatments are working. The test's diagnostic accuracy is 85%, correctly detecting cancer 83% of the time and ruling out cancer 92% of the time.
A study published in JAMA Oncology found significant disparities in breast biopsy delays among non-white women, with Black women experiencing the longest delays. Structural racism within healthcare facilities and screening site-specific factors contribute to these disparities.
Researchers found that circulating cancer cells form metastases mainly during sleep phases, with higher cell division rates at night, suggesting a link between hormone regulation and tumor growth. This discovery highlights the need for healthcare professionals to record the time of biopsies to ensure comparable data.
A prospective study compared CEM and MRI for NAT response assessment in patients with breast cancer. CEM yielded comparable assessments of lesion size and RECIST categories as MRI, but with lower sensitivity for pathologic complete response. Delayed CEM acquisition detected residual ductal carcinoma in situ (DCIS).
A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...
A multi-institutional study found that diagnostic mammography outcomes vary across racial and ethnic groups, with higher accuracy in non-Hispanic white women and lower accuracy in Hispanic women. The study suggests that imaging facility and concurrent use of breast ultrasound or MRI may contribute to some disparities.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that diagnostic mammogram accuracy differed across racial and ethnic groups. Asian/Pacific Islander women were more likely to receive false-positive reports, while non-Hispanic Black women were more likely to receive false-negative reports.
A new study found that a healthy, plant-based diet was associated with a 14% lower risk of breast cancer in postmenopausal women. Researchers analyzed data from over 65,000 participants and categorized their diets into different food groups, concluding that choosing healthy plant-based foods is likely helpful for cancer prevention.
Researchers developed a novel nanoparticle to deliver ARL67156, an enzyme inhibitor that prevents ATP degradation into adenosine, selectively targeting solid tumors. The treatment substantially suppressed tumor growth and resulted in prolonged survival in mouse models.
A new study published in JAMA found that digital breast tomosynthesis (DBT) may reduce the chance of an advanced cancer diagnosis for women with the densest breasts and highest risk, but not all women. DBT had additional advantages for women with specific risk profiles, including a higher rate of detection of small invasive breast canc...
A new study found that parabens increase the growth, invasion, and expression of genes linked to cancer in breast cancer cells from Black women. This effect was more pronounced in Black cell lines compared to white cell lines.
A new study suggests that probiotic bacteria, particularly Lactobacillus, may enhance the effectiveness of tamoxifen and other endocrine-targeted therapies in reducing ER+ breast cancer risk. The researchers found elevated levels of Lactobacillus in breast tissue of mice treated with tamoxifen, leading to decreased breast tumor formation.
A proteomic study of 2,002 tumors identified 11 distinct molecular subtypes across 14 tissue-based cancer types, including breast, lung, and brain cancers. These subtypes provide new insights into the deregulated pathways and processes in tumors that make them cancerous.
A new genetic study published in Nature Genetics found that roughly one in five invasive breast cancers following ductal carcinoma in situ (DCIS) are genetically unrelated to the original DCIS. The findings provide a deeper understanding of DCIS biology and suggest that DCIS should be considered a risk factor for the development of inv...
Scientists have discovered a new molecule, ERX-41, that effectively targets and kills cancer cells with elevated endoplasmic reticulum stress. The compound exploits the weakness in cells not previously targeted by other drugs, showing promise for patients with triple-negative breast cancer and other hard-to-treat cancers.
A recent study identified 34 novel genes that contribute to endocrine resistance in breast cancer using dynamic gene expression analysis. The researchers found that these genes are differentially expressed in both estrogen receptor-positive and triple-negative breast cancers, suggesting shared genetic mechanisms underlying resistance d...
A recent Oregon State University study found that a mindfulness-based intervention delivered via videoconference was a feasible treatment option for survivors of breast and gynecologic cancers. The pilot study showed that participants learned mindfulness exercises, gained insight into sexual interest, and appreciated the group's suppor...
The American Society for Nutrition presents the latest findings on ultra-processed foods, genetic influence on eating habits, and diet quality. Research highlights the risks of ultra-processed foods, the potential impact of genetics on food preferences, and the importance of healthy diets for preventing chronic diseases.
A recent study by McMaster University researcher Timothy Whelan and his team has identified a specific group of patients with early stage breast cancer who can effectively treat their disease with just surgery and endocrine therapy. The study found that the recurrence of cancer in these patients was just 2.3% without radiotherapy.
ERX-41 effectively kills various cancer types, including triple-negative breast cancer, by exploiting a previously unexploited vulnerability. The compound targets endoplasmic reticulum stress and increases protein folding errors, leading to cancer cell death, offering new hope for treating these aggressive cancers.